Yazar "Carr, Brian" seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Alpha-fetoprotein and albumin inversely relate to each other and to tumor parameters in patients with hepatocellular carcinoma(Kare Publ, 2024) Carr, Brian; Guerra, Vito; Ince, Volkan; Isik, Burak; Yilmaz, SezaiBackground and Aim: Alpha-fetoprotein (AFP), an oncofetal protein and biomarker in hepatocellular carcinoma (HCC), has unclear roles and ac-tions.To evaluate the relationships between AFP, liver function tests, and HCC aggressiveness. Materials and Methods: A retrospective analysis of an HCC patient data-base was conducted to examine the relationships between baseline serum AFP values, liver function tests, and tumor characteristics. Results: Statistically significant positive trends were observed between AFP levels and both AST and bilirubin, along with negative trends between AFP and albumin. Significant correlations were also found between AFP and MTD, multifocality, and PVT. Increases in MTD, multifocality, and PVT were noted even at low AFP levels, indicating both AFP-independent and AFP-dependent processes. However, these parameter changes were minimal compared to the substantial changes in AFP levels. Relationships between AFP-related liver and tumor characteristics were found to be sim-ilar but inverse to those for albumin, with normal albumin levels associated with more favorable tumor characteristics. Additionally, serum levels of albumin and AFP were inversely related. Conclusion: AFP and albumin levels significantly, but inversely, correlate with tumor parameters, suggesting that albumin may suppress HCC func-tions and could serve as a potential prognostic marker.Öğe LIVING DONOR LIVER TRANSPLANTATION FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: SINGLE CENTER EXPERIENCE(2023) Ersan, Veysel; Ince, Volkan; Usta, Sertaç; Barut, Bora; Samdancı, Emine; Carr, Brian; Yılmaz, SezaiIntroduction: Hepatic epithelioid hemangioendothelioma (HEHE) is a rare malignant vascular tumor of the liver. Liver transplantation (LT) is the treatment of choice for patients with advanced-stage HEHE. The aim of this study is to present the results of HEHE patients treated with living donor LT. Material and Method : Between March 2002 and December 2021, 3121 liver transplantations were performed at our institute, 2632 of these were living donor LT. Demographic characteristics, symptoms and clinical findings, laboratory, radiological, and posttransplant histopathological examinations, recurrence rates, disease-free survival, and overall survival rates of the patients were analyzed. Results: The mean age was 41.7 years and %57.6 of the patients were women. Five patients were referred to our institute with signs of chronic liver failure. Four of these patients (57.1%) had Budd-Chiari syndrome. The median follow-up was 35.0 (12.8 - 119.4) months. In all patients, the tumor recurrence rate after transplantation was 71.4%. The overall survival rate for 1 and 5 years was 100 – 57.1% and the disease free survival rate for 1 and 5 years was 71.4 - 38.1%, respectively. Conclusion: Living donor liver transplantation can be considered a viable treatment option for selected HEHE patients. However, multicenter collaborations are crucial to enhance our understanding of this rare malignancy and improve treatment outcomes for these patients.Öğe A Recipient and Donor Both Have COVID-19 Disease. Should We Perform a Liver Transplant?(Springer, 2021) Tuncer, Adem; Akbulut, Sami; Baskiran, Adil; Karakas, Ezgi Erdal; Baskiran, Deniz Yavuz; Carr, Brian; Yilmaz, SezaiCoronavirus 2019 (COVID-19) is a new infectious disease that continues to spread globally. There is growing concern about donor-induced transmission of Coronavirus 2 (SARS -CoV-2). For liver transplantation, the COVID-19 PCR test is routine, in addition to epidemiological history and clinical and radiological examination 24-48 h before surgery. One of the liver transplant candidates was found to be infected with COVID-19, as well as the planned donor candidate. Since COVID-19 will be a high-risk operation for both the recipient and the donor, the operation was postponed by giving medical treatment. After the treatment and quarantine process was over, the patient and the donor then had a negative COVID-19 PCR test and the patient received a living donor liver transplant. We present a case of donor and recipient who initially both tested positive for COVID-19. This liver transplantation scenario has not previously been reported in the literature.